Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01162863
Other study ID # 08-028LUB
Secondary ID
Status Completed
Phase N/A
First received July 9, 2010
Last updated January 22, 2013
Start date November 2010
Est. completion date December 2012

Study information

Verified date January 2013
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit. IBS is further subcategorized as three types according to the predominant bowel movement pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed-IBS (IBS-M). The exact causes of IBS remain incompletely understood, but proposed mechanisms include abnormal motility, visceral hypersensitivity, abnormal brain-gut interactions, psychological distress, and altered GI tract motility.

Lubiprostone, a novel drug that works by activating the colonic ClC-2 chloride channel, has been approved for use in patients with chronic idiopathic constipation and recently approved for the treatment of IBS-C in women aged 18 and older. By activating the ClC-2 chloride channel in the colon, lubiprostone allows more fluid secretion into the intestinal lumen which leads to softer stool consistency. In phase III clinical trials, patients with IBS-C receiving lubiprostone have reported improvements in many symptoms such as abdominal pain and constipation. However, there is limited physiologic data to explain how exactly lubiprostone improves IBS-C symptoms.

The Smartpill is a novel non-digestible capsule that is capable of measuring intraluminal pH, pressure, and temperature in the gastrointestinal (GI) tract. Smartpill has been shown to accurately measure whole gut as well as regional (i.e. stomach, small bowel, colon) transit time.

The primary aim of this study is to determine the effects of lubiprostone on whole GI tract transit, colonic transit, motility, and intraluminal pH in patients with IBS-C through evaluation with the Smartpill. The investigators propose to study the effect of lubiprostone vs. placebo on these parameters, and secondarily to evaluate changes in these parameters with differing doses of lubiprostone.

The investigators hypothesize that lubiprostone will increase whole GI and colonic transit compared to placebo in patient with IBS. the investigators do not expect a change in intraluminal pH with lubiprostone compared to placebo.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males or females >18 years of age

- Meet Rome III criteria for IBS[2]:

- Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following:

1. Improvement with defecation

2. Onset associated with a change in frequency

3. Onset associated with a change in form (appearance) of stool

- *Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

- Fulfill the Rome III stool consistency criteria for IBS-C[2]

- Hard or lumpy stools for >25% of bowel movements

- Loose (mushy) or watery stools for <25% of bowel movements

- Capable of independently completing all requirements of the study including returning for required visits

- Able to provide written informed consent for study participation

- Willing to discontinue prohibited medications during study participation

- Documentation of a normal colonoscopy within last 5 years if over age 50 years (or sigmoidoscopy if less than age 50)

- Documentation of normal TSH, CBC and electrolyte panel within prior 3 years

- Females of childbearing potential must have a negative urine or serum pregnancy test at screening

- Females of childbearing potential must use an effective means of contraception during the course of the study

- Hormonal (oral, injectable, implantable, cervical/vaginal rings or patches)

- Double-barrier (condoms and/or diaphragm with spermicides) or intrauterine devices provided under the care of a health care professional

- Abstinence, in this case documentation of counseling will be recorded

Exclusion Criteria:

- Unable to understand or provide written informed consent

- Pregnant or nursing

- Patients with IBS-D, IBS-M or unsubtyped IBS by Rome III criteria[2]

- IBS with diarrhea (IBS-D)

1. Loose (mushy) or watery stools for >25% of bowel movements

2. Hard or lumpy stools for <25% of bowel movements

- Mixed IBS (IBS-M)

1. Hard or lumpy stools >25% of bowel movements

2. Loose (mushy) or watery stools for >25% of bowel movements

- Unsubtyped IBS

1. Insufficient abnormality of stool pattern to meet criteria for IBS-C, IBS-D or IBS-M

- Documented allergy or intolerance to lubiprostone

- Failure of balloon expulsion test

- Inability to expel 50cc balloon within 1 minute

- Use of drugs known to affect gastrointestinal motility

1. Laxatives (stable doses of fiber taken for minimum of 4 weeks will be allowed)

Osmotic laxatives:

Magnesium hydroxide, Polyethylene glycol,Lactulose, Sorbitol

Stimulant laxatives:

Bisacodyl, Anthraquinones (senna), Misoprostol

2. Prokinetic agents:

Metoclopramide, domperidone, erythromycin

3. Anti-diarrheal agents:

Loperamide, Diphenoxylate, Bismuth

4. Anti-spasmotics:

Dicyclomine, Hyoscyamine

5. Opioid, narcotic, opioid/narcotic-containing analgesics:

Morphine, Hydrocodone, Codeine, Methadone, Propoxyphene

6. Probiotics

7. Systemic antibiotics within last 3 months

8. Recently initiated antidepressants (stable dose for >2 months for non-GI conditions will be allowed)

9. Benzodiazepines * Subjects taking prohibited medications will be required to stop these at the screening visit and remain off of them until completion of the study.

- Initiation of dietary changes potentially altering bowel transit within 4 weeks

- Comorbid medical problems that may affect gastrointestinal transit or motility

1. Previous surgery involving the stomach, small bowel or colon (prior appendectomy, cholecystectomy, polypectomy allowed)

2. Previous history of small bowel obstruction for any reason

3. History of any gastrointestinal malignancy

4. History of dyssynergic defecation

5. Unexplained nausea and vomiting

6. History of inflammatory bowel disease (Crohn's or ulcerative colitis)

7. History of microscopic colitis (lymphocytic or collagenous colitis)

8. History of Hirschsprung's disease

9. Severe or complicated diverticular disease

10. Chronic pancreatitis

11. History of celiac disease

12. History of eating disorders (anorexia nervosa or bulimia)

13. Cirrhosis

14. Chronic hepatitis B or C infection

15. HIV infection

16. Diabetes

17. Systemic sclerosis (scleroderma)

18. Amyloidosis

19. Untreated thyroid disease

20. Chronic pulmonary disease

21. Severe renal insufficiency or renal failure

22. Current or recent history (within last 6 months) of:

Diverticulitis, Duodenal or gastric ulcer, Acute pancreatitis, Ileus

- Contraindications to SmartPillĀ® (in addition to above):

Cardiac pacemaker, defibrillator, or other implanted electromagnetic device, Known Zenker's diverticulum, Dysphagia

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
Lubiprostone
lubiprostone taken either at a dose of 8 mcg po bid for 28 days or 24 mcg po bid for 28 days
Placebo
taken orally for 28 days

Locations

Country Name City State
United States University of Michigan Health System Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Takeda Pharmaceuticals North America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on whole gut transit time in adult patients with IBS-C 21-28 days No
Secondary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on colonic transit time in adult patients with IBS-C 21-28 days No
Secondary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on whole gut motility pattern in adult patients with IBS-C 21-28 days No
Secondary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on colonic motility pattern in adult patients with IBS-C 21-28 days No
Secondary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on whole gut pH pattern in adult patients with IBS-C 21-28 days No
Secondary Compare the effects of 4 weeks of lubiprostone 8 mcg bid and lubiprostone 24 mcg qd to placebo on colonic pH pattern in adult patients with IBS-C 21-28 days No
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A